A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

por Li, Ning, Wu, Tao, Hong, Yong-Gui, Guo, Yan-Zhen, Cheng, Yu-Feng, Ma, Yi-Jie, Bie, Liang-Yu, Cui, Dong-Hai, Gao, Xiao-Hui, Tan, Bing-Xu, Li, Bao-Sheng, Luo, Su-Xia, Wang, Jun-Sheng
Publicado 2022